



Proton Radiation Therapy Technology and Clinical Indications

Niek Schreuder

Vice President and Chief Medical Physicist

Marcio Fagundes MD - Medical Director

Matt Ladra MD (Pediatrics)

Allen Meek MD

Tamara Vern Gross MD

Provision Health Alliances



Proton Therapy Alliances



Provision Health Alliance (PHA)

A comprehensive clinical outpatient healthcare center consisting of multiple physician practice groups, comprehensive diagnostic imaging, advanced chemotherapy and radiation therapy, wellness center, physical therapy, a cyclotron and nuclear pharmacy, and clinical trials and research capabilities.



Provision Center for Proton Therapy (PCPT)

The key cancer radiation therapy component of PHA at Dowell Springs which together with the rest of PHA distinguishes PHA from all other outpatient cancer centers in the world. Currently, there are 11 proton centers in the US.



ProNova Solutions, LLC (ProNova)

A US-based developer, manufacturer, and distributor of multi-room proton therapy equipment and solutions which together with PHA and PCPT distinguishes us from all other proton therapy manufacturers and centers in the world.




Provision Center for Proton Therapy Facility – 1st Floor

ProNova
Treatment rooms

Treatment rooms

Cyclotron




Physics of Protons

- Protons are directly ionizing particles
- Energy Loss is proportional to $1/v^2$
 - Bragg Peak
 - finite range in matter
- Multiple Scattering
 - lateral broadening of beam
- Nuclear interactions

The Physics of Protons


Depth Dose Curves for Different Treatment Modalities



Where do we get the Protons?

Protons are the nucleus of the hydrogen atom.

Protons are created by stripping (ionizing) the electron from the hydrogen atom.



The Hydrogen Atom



Accelerating Protons

In order for protons to be clinically useful for radiotherapy, they must be accelerated to high energy.

Radiotherapy is performed with protons of energy up to 250 MeV (mega-electron volts). **mega = $10^6 = 1,000,000$**

- “room temperature” atoms have energies of ~25 meV (milli-electron volts). **milli = $10^{-3} = 1/1000$**
- so we have to increase their energy by a factor of ~**10 billion** for clinical use.

A 200 MeV proton travels at ~1/2 the speed of light.

There are several techniques for accelerating protons:

Synchrotrons, linear accelerators, **cyclotrons**

“High Energy” can be Misleading


electron volts in perspective

- A light bulb consumes $\sim 10^{20}$ eV/second.
- Bowl of Wheaties $\sim 10^{24}$ eV.
- A fly travelling only 1 meter/second has an energy of **~ 10 billion MeV.**

Protons are tiny – they are $\sim 10^{-15}$ meters in radius and have a mass of $\sim 10^{-27}$ kilograms.

How a Cyclotron Works

5. High energy protons are kicked out.



1. Protons (ionized hydrogen) are injected at low energy.

2. Voltage alternates to give the protons a “kick” every time they cross the gap.


3. Magnetic field keeps protons bound in a circular orbit.

4. As the proton's energy increases, its orbital radius increases.

Early Cyclotrons


1930's

First Cyclotron, 1931



4 inch diameter
80,000 eV

Original publication in 1932.




Ernest Lawrence won the Nobel Prize in 1939 for his work on the cyclotron.




How do we use Protons

- *The same way than x-rays – conventional radiotherapy*


Classical Radiation Therapy




Classical Proton Therapy: *oldest form of IMRT – depth dose modulation*




Beam Delivery Systems



Active scanning






Pencil Beam Scanning Proton Therapy: Best form of IMRT



Spot Scanning Principle

*Pictures -
With
compliments
from PSI*



Pencil Beam Scanning (PBS)

– *Filling the target with spheres of Radiation dose*




**“There is no advantage
whatsoever to irradiating
uninvolved healthy tissue”**

Dr. Herman Suit
Harvard / MGH Proton Center (1)

(1) Herman Suit, “The Grey Lecture 2001: Coming Technological Advances in Radiation Oncology,” International Journal of Radiation Oncology Biology Physics 53 No. 4 (2002): 798-809.


The Goal of Radiation Therapy for 100 years:




Potential improvement in quality of life

Cost savings by decreasing complications

How does Radiation Kill cells ?




How does Radiation Kill cells ?



The Value of Protons

Protons are physically superior to X-rays:





Protons



X-Rays do not stop
Continue to travel
into normal tissues
beyond the target

Individualized treatment - NTCP-models and *in silico* studies


With Compliments – Dr Hans Langendijk - UMCG



Conversion of: *Dose difference*
to:
Clinical benefit
(*NTCP-value*)



Proton therapy → Categories of indications



Source: Horizon scanning report (Health council of the Netherlands 2009)

With Compliments – Dr Hans Langendijk - UMCG

Proton Therapy – Past and Current Environment

- **First patient treatment in the U.S. occurred at Berkeley in 1954**
 - First IMRT treatment didn't occur until the early 1990s
- **Harvard - MGH began treating patients in 1961**
- **The first hospital based proton center in the U.S. was built at the Loma Linda University Medical Center in 1990**
 - Loma Linda initially treated prostate, brain, and some head and neck tumors
- **Currently: 15 operating centers in the U.S. and over 30 worldwide**
 - There are another 30+ proton centers in development in the U.S.
- **Medicare has paid for proton therapy since 1997**
- **Every major national insurance carrier has paid for proton therapy**

What Cancers Can Protons Treat?

Classic indications:

Base of skull tumors


Eye (uveal) melanomas

Brain tumors

Pediatric tumors

Spinal / Paraspinal tumors

Prostate cancers



Lung

Liver

Breast

Esophagus

Pelvic tumors

Large sarcomas

Mediastinal tumors

Reirradiation of recurrent tumors




Pediatric Treatments

The Value of Protons


Protons are physically superior to X-rays:

Protons




**Protons avoid unnecessary radiation
to heart, lungs, intestines delivered by X-rays**

X-Rays do not stop
Continue to travel
into normal tissues
beyond the target



Medulloblastoma Longitudinal IQ

IMRT vs. IMPT



Quality of Life





Original article

Quality of life outcomes in proton and photon treated pediatric brain tumor survivors

QOL for children 2-18 yrs treated at MGH (n=57) or Stanford (n=60)

Protons scored 10 pts higher in Psychosocial and Physical domains vs photons


Significant differences seen in Total QoL scores for Medulloblastoma, Ependymoma/High Grade Glioma, and Low Grade Glioma



Second Malignancy

Incidence of Second Malignancies Among Patients Treated With Proton Versus Photon Radiation

Christine S. Chung, MD, MPH,* Torunn I. Yock, MD, MCh,[†] Kerrie Nelson, PhD,[‡]
Yang Xu, MS,[§] Nancy L. Keating, MD, MPH,^{§,¶} and Nancy J. Tarbell, MD^{†,||}






558 proton pts treated from MGH (1973 to 2001) compared with 558 matched photon pts (SEER)

Hazard ratio
=0.52
(CI 0.32-0.85,
p=0.009)

Recent Cases At Provision

Bifocal Germinoma



WHOLE VENT - Approved (TREATMENT PLANNING CT 1mm)



cGy



WHOLE VENT - Approved (TREATMENT PLANNING CT 1mm)




Dose axis display options: Absolute values Relative max dose value Relative reference value (cGy)

Dose Statistics: Class of Goals Biological Response Fractionation Schedule Beams (Current) Energy Layer (Current)

ROI statistics: ROI statistics

Dose	ROI	ROI vol. [cm ³]	Dose [cGy]	Min	Max	Average	SD	ST	% outside grid
Plan dose: 2FD 3FD WHOLE VENT...	Brain	1349.98	5	0	18	1034	934	2465	0%
Plan dose: 2FD 3FD WHOLE VENT...	Clinical	0.32	2454	2453	2454	2466	2466	2467	0%
Plan dose: 2FD 3FD WHOLE VENT...	Hypothalamus	0.50	2436	2437	2460	2462	2463	2463	0%
Plan dose: 2FD 3FD WHOLE VENT...	Left Hippocampus	1.42	2393	2395	2342	2431	2442	2480	0%
Plan dose: 2FD 3FD WHOLE VENT...	Left Eye	0.47	0	0	0	4	1	25	0%
Plan dose: 2FD 3FD WHOLE VENT...	Left Optic Nerve	0.35	23	23	29	591	140	2476	0%
Plan dose: 2FD 3FD WHOLE VENT...	Left Temporal Lobe	79.15	19	29	35	813	541	2445	0%
Plan dose: 2FD 3FD WHOLE VENT...	Pituitary	0.22	2363	2378	2401	2468	2482	2499	0%
Plan dose: 2FD 3FD WHOLE VENT...	Right Hippocampus	1.43	2353	2358	2385	2434	2439	2469	0%
Plan dose: 2FD 3FD WHOLE VENT...	Right Eye	0.48	0	0	0	4	1	25	0%
Plan dose: 2FD 3FD WHOLE VENT...	Right Optic Nerve	0.38	11	15	18	543	91	2450	0%
Plan dose: 2FD 3FD WHOLE VENT...	Right Temporal Lobe	88.86	12	15	22	790	448	2442	0%

Tectal Glioma 50.4 CGE




Prostate Cancer

Radiotherapy for Prostate Cancer

Conventional radiotherapy X-rays (IMRT) exposes more healthy tissue to radiation

**Conventional radiotherapy
X-rays (IMRT)**




**Higher dose to healthy tissues:
Pelvis, rectum and bladder**

Dose level	
Blue	13%
Green	51%
Purple	63%
Yellow	76%
Red	95%

Tumor



**Proton
therapy**




**Less healthy tissue exposed to
radiation with protons**

Proton and IMRT – Prostate Plan

IMRT (10 liters)




PROTONS





Lung Cancer

Why Protons for Lung Cancer ?

Conventional radiotherapy X-rays (IMRT)



Protons



Difference


Protons decrease unnecessary dose to:

- Left lung
- Esophagus
- Heart
- Spinal cord

Clinical Case 1

Ri

onth



M.D. Anderson treatment related toxicity data for inoperable locally advanced lung cancer:

NSCLC treated with radiation therapy + chemotherapy¹








	3D CRT	IMRT	Protons
Dose	63 Gy	63 Gy	74 CGE
% patients stage IIIA-B2	87%	91%	87%
Toxicity			
Esophagitis – G3+	18%	44%	5% ↓
Pneumonitis – G3+	30%	9%	2% ↓

¹ Samir Sejpal et al., “Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer,”
Cancer. 2011 Jul 1;117(13):3004-13

Lung Cancer Proton Therapy Trials

Study name	Trial type	Modalities	Description	Selection criteria (inoperable)
<u>Proton with chemo</u>				
M.D. Anderson	Phase II	Protons and chemo	-Primary goal is to improve survival -Chemo and 74 CGE of proton therapy	Stage IIIA and IIIB
Loma Linda	Phase I/II	Protons and chemo	-Chemo with accelerated proton therapy -5 week RT (first two weeks – daily; final three weeks – twice daily)	Stage II, IIIA or IIIB
University of Florida	Phase II	Protons and chemo	-Chemo with higher 74 CGE dose delivered by protons	Stage IIIA or IIIB
UPENN	Phase I/II	Protons and chemo	- Chemo with 5.5 – 7.5 weeks of proton radiation (total dose not disclosed)	Stage IIIA that are eligible for surgery
UPENN	Phase I	Protons and Nelfinavir	-Goal is to test the highest safest dose of proton therapy that can be given concurrently with drug	Stage IIIA or IIIB
<u>Randomized</u>				
M.D. Anderson	Phase II	Protons and x-rays	-Randomize between x-rays and protons	Stage II-IIIB
PCG	Phase III	Protons and x-rays	-Randomize between x-rays and protons	Stage IIIA - IIIB
<u>Hypofractionation</u>				
M.D. Anderson	Phase I	Protons	-Hypofractionating starting at 45 Gy in 15 Fx to 60 Gy in 15 Gy	-NSLC, small cell lung cancer, thymic or carcinoid tumors
University of Florida	Phase II	Protons	Hypofractionating: -48 CGE in 4 fx (peripherally located) -60 CGE in 10 fx (centrally located)	Stage I
<u>Dose escalation</u>				
M.D. Anderson	Phase II	Protons	-Dose escalation to 87.5 CGE in 35 Fx	Stage IA, IB, and selected stage II

Rectal Re-irradiation




Breast Cancer


Breast Cancer Treatment

- **Many breast cancer patients will receive radiation therapy as part of their course of treatment**
- **Patients are at risk for post treatment complications resulting from radiation to the heart, lungs and contralateral breast**
 - These risks may increase if patients:
 - a) Receive cardio-toxic chemotherapy drugs
 - b) Have smoking history
 - c) Left sided breast cancer
- **Protons can spare critical structures and can deliver approximately 10 times less radiation to the heart than conventional X-Ray radiation**


Coronary Exposure to Radiation in Conventional Radiotherapy for Breast Cancer



Stenosis of the main coronary artery left anterior descending (LAD)



Use Protons



Spare the heart
and coronaries

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

MARCH 14, 2013

VOL. 368 NO. 11

Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

Sarah C. Darby, Ph.D., Marianne Ewertz, D.M.Sc., Paul McGale, Ph.D., Anna M. Bennet, Ph.D.,
Ulla Blom-Goldman, M.D., Dorthe Brønnum, R.N., Candace Correa, M.D., David Cutter, F.R.C.R.,
Giovanna Gagliardi, Ph.D., Bruna Gigante, Ph.D., Maj-Britt Jensen, M.Sc., Andrew Nisbet, Ph.D.,
Richard Peto, F.R.S., Kazem Rahimi, D.M., Carolyn Taylor, D.Phil., and Per Hall, Ph.D.

Sweden and Denmark: Population-based study of 2168 pts post-radiotherapy for Breast Cancer

Risk of major coronary events: Myocardial infarction
Coronary revascularization
Death from ischemic heart disease

...were correlated with mean radiation dose delivered to the heart.

The Risk of major coronary event increases by 7.4% per gray of exposure to the heart¹

Heart toxicity (cont)

ASTRO states that *“in patients with breast cancer, it is recommended that the irradiated heart volume be minimized to the greatest possible degree without compromising the target dose”*¹

	3DCRT	IMRT	Tomo	Protons
LAD mean dose	23.7	19.9	10.6	5.8 Gy
Heart mean dose	7.3	8.2	10.5	0.9 Gy
Total Lung V5 Gy	33.6%	54.6%	46.3%	20.6%
Contral. Breast mean	1.5	3.9		0.2 Gy
Unspecified normal tissue volume ≥ 10 Gy (cc)	2817			353

57.5% reduction in the Risk of major coronary event

¹ Gagliardi et al., “Radiation dose-volume effects in the heart,” Int J Radiat Oncol Biol Phys. 2010; 77: S77-S85


² Fagundes, M. et al. “Cardiac Sparing Adjuvant Proton Radiotherapy,” J Clin Oncol. 2013.

“Direct Radiation Complications Never Occur In Unirradiated Tissues”

Dr. Herman Suit
Harvard / MGH Proton Center (1)

(1) Herman Suit, “The Grey Lecture 2001: Coming Technological Advances in Radiation Oncology,” International Journal of Radiation Oncology Biology Physics 53 No. 4 (2002): 798-809.

Treatment Modality Evolution



Cost of Complications

- The average lifetime cost of a severe heart attack has been estimated to be about \$1 million¹
- ~75% of health care costs in the U.S. goes to the treatment of chronic diseases²
- In 2010 the cost of cardiovascular disease / stroke in the U.S. was about \$432 billion (1 in every 6 dollars spent on healthcare)³

The best way to reduce the overall cost of cancer care is to eliminate the chronic side effects of treatment

¹ National Business Group On Health.

² “Chronic Disease Prevention and Health Promotion”. Centers for Disease Control and Prevention. August 5, 2013.


<http://www.cdc.gov/chronicdisease/index.htm>

³ Mensah G, Brown D. An overview of cardiovascular disease burden in the United States. *Health Aff* 2007; 26:38-48.

The Future of Proton therapy

Leveraging Technology

- **Superconducting magnets have multiple benefits**
 - Dramatically smaller size, weight, and power
 - 2X higher magnetic field, 0.5X bend radius
- **ProNova leverages superconducting magnet technology**
 - Maintains 360° rotation similar to radiation therapy
 - Ample room for full ring imaging at isocenter
 - Simplified shipping and installation reducing cost and time to market



SC360 Efficient 1, 2, 3+ Room Solution

High Current
Continuous beam
Cyclotron

Permanent Magnet
Constant Energy Beamline


Dual Energy Selection
Systems
< 1 sec Room Switching

360° Superconducting
Gantry

PBS with
Variable Spot Size
App's & Comp's
0.5 sec Layer Change

Dual Energy CBCT
Integrated with Positioner
5 RPM, Spiral Capable

Auxiliary Positioner
Calibration
PET at Isocenter



Open square room provides improved patient access


Open room provides clear access for lasers, projectors, Optical imaging, & intercom

Projection screens provide easy review of therapy information

ProNova R&D and Manufacturing Facility



U.S. Proton Therapy Centers



-
- In Operation (15)
 - Under Construction (13)
 - Under Development (21)
-

- 1 Massachusetts General Hospital, Boston
- 2 Loma Linda University Medical Center, Calif.
- 3 Midwest Proton Radiotherapy Institute, Bloomington
- 4 MD Anderson Cancer Center, Houston (PTCH)
- 5 University of Florida Proton Therapy Institute, FL
- 6 ProCure Proton Therapy Center Oklahoma City, O
- 7 University of Pennsylvania Health System, Philadelphia
- 8 Hampton University Proton Therapy Institute, Hampton
- 9 ProCure Proton Center, Chicago
- 10 ProCure Proton Center, New Jersey
- 11 ProCure Proton Therapy Center, Seattle
- 12 Washington University, St. Louis
- 13 Provision Center for Proton Therapy, Knoxville
- 14 Scripps Proton Therapy, San Diego
- 15 Willis Knight Shreveport LA ProvisionProton.com

The future of Proton Therapy

- All truth passes through three stages.
 - *First, it is ridiculed.*
 - *Second, it is violently opposed.*
 - *Third, it is accepted as being self-evident –*
 - *Arthur Schopenhauer (1788 1860)*



The Truth of Proton Therapy is now almost through the second Phase

Provision Center for Proton Therapy



Thank You